News Medical on MSN4d
Scientists analyze virus protein structure to advance RSV vaccines
In most people, the lung-infecting pathogens known as respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) ...
Macau Business1h
ArkBio Announces Successful Completion of Enrollment and Dosing for Phase 1 Clinical Study of AK0610,...
(“ArkBio”) announced today the successful enrollment and dosing of all participants in a Phase 1 clinical study of AK0610, a ...
cidrap.umn2d
US respiratory virus activity remains low ahead of holiday season
Respiratory virus activity remained low in the United States last week, with COVID levels continuing to decline, but ...
Science Daily5d
Eradivir's EV25 therapeutic reduces advanced-stage influenza viral loads faster, more thoroughly in preclinical studies than current therapies
A research article shows that Eradivir's patent-pending antiviral therapeutic called EV25 reduces lung viral loads of advanced-stage influenza in preclinical studies quicker and more effectively than ...
earth4d
How the COVID-19 virus travels deep inside our lungs
New COVID-19 research uncovers viral behavior insights, driving innovative treatments with Northwestern Medicine's support.
Medscape9d
Nirsevimab Resistance Mutations Rare in RSV, Study Shows
Widespread distribution of nirsevimab to infants with respiratory syncytial virus infection raised concerns about potential ...
Business Insider3d
Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology
targeting respiratory syncytial virus (RSV) and malaria utilizing the company’s proprietary C1 protein production platform to provide globally accessible treatment options for underserved populations.